Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba

Anton Andonov; Kamran Kadkhoda; Carla Osiowy; Kelly Kaita

doi:10.1155/2013/273856

Canadian Journal of Gastroenterology (Jan 2013)

Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba

Anton Andonov,
Kamran Kadkhoda,
Carla Osiowy,
Kelly Kaita

Affiliations

Anton Andonov: Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
Kamran Kadkhoda: Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada
Carla Osiowy: Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
Kelly Kaita: University of Manitoba, Department of Internal Medicine, Winnipeg, Manitoba, Canada

DOI: https://doi.org/10.1155/2013/273856
Journal volume & issue: Vol. 27, no. 7
pp. 414 – 416

Abstract

Read online

BACKGROUND: Traditional therapy with pegylated interferon and ribavirin combined with the new protease inhibitors boceprevir or telaprevir has demonstrated improved outcomes in hepatitis C virus (HCV)-infected patients. Prevalence data regarding pre-existing drug-resistant variants to these two new virus inhibitors in the Canadian population are not available.

Published in Canadian Journal of Gastroenterology

ISSN: 0835-7900 (Print); 1916-7237 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://onlinelibrary.wiley.com/journal/1720

About the journal